Part D Formulary Negotiations Take “Portfolio Approach” For AstraZeneca
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca has adopted a "portfolio approach" in its negotiations with prescription drug plans to gain strong Medicare Part D formulary positions, Chief Financial Officer Jonathan Symonds said
You may also be interested in...
Wyeth Stands Its Ground, Avoids Premarin Discounts Under Part D
Premarin is discounted roughly 2% for Part D enrollees at the retail pharmacy level, compared to an average drug discount of 35%, PCMA says.
Wyeth Stands Its Ground, Avoids Premarin Discounts Under Part D
Premarin is discounted roughly 2% for Part D enrollees at the retail pharmacy level, compared to an average drug discount of 35%, PCMA says.
Express Scripts Says Customers Support Removal Of Several Pfizer Products From Formulary
Decision to drop Lipitor and Norvasc from its 2006 formulary represents an opportunity for savings without compromising health outcomes, the PBM says.